---
schema_version: "secwatch.filing_event.v1"
accession: "0001731122-25-001591"
form_type: "8-K"
ticker: "AVXL"
cik: "0001314052"
company_name: "ANAVEX LIFE SCIENCES CORP."
filed_at: "2025-11-25T23:59:59+00:00"
generated_at: "2026-05-16T16:51:04.049550+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Anavex Life Sciences Reports Fiscal 2025 Q4 Net Loss of $9.8M and CHMP Negative Vote for Blarcamesine

## Summary
- Net loss for Q4 fiscal 2025 was $9.8M ($0.11 per share), compared to net loss of $11.6M ($0.14) in Q4 fiscal 2024.
- Cash and cash equivalents were $102.6M at September 30, 2025, down from $132.2M a year ago; current cash over $120M with >3 year runway.
- CHMP of EMA issued a negative trend vote on the Marketing Authorisation Application for blarcamesine; Anavex intends to request re-examination.
- Positive topline results from Phase 2 study of ANAVEX3-71 for schizophrenia: safe and well-tolerated, primary safety endpoint met.
- Research & development expenses for the quarter were $7.3M, down from $11.6M in the prior year quarter.

## SEC filing metadata
- accession: 0001731122-25-001591
- form_type: 8-K
- ticker: AVXL
- cik: 0001314052
- company_name: ANAVEX LIFE SCIENCES CORP.
- filed_at: 2025-11-25T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314052/000173112225001591/0001731122-25-001591-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314052/000173112225001591/e7068_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001731122-25-001591
- JSON: https://secwatch.observer/filing/0001731122-25-001591.json
- Plain text: https://secwatch.observer/filing/0001731122-25-001591.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.